当前位置: 首页 >> 检索结果
41. Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-Analysis of TWILIGHT and TICO Randomized Trials.
作者: Usman Baber.;Yangsoo Jang.;Angelo Oliva.;Davide Cao.;Birgit Vogel.;George Dangas.;Samantha Sartori.;Alessandro Spirito.;Kenneth F Smith.;Mattia Branca.;Timothy Collier.;Stuart Pocock.;Marco Valgimigli.;Byeong-Keuk Kim.;Myeong-Ki Hong.;Roxana Mehran.
来源: Circulation. 2024年149卷8期574-584页
Dual antiplatelet therapy with a potent P2Y12 inhibitor coupled with aspirin for 1 year is the recommended treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). As an alternative, monotherapy with a P2Y12 inhibitor after a short period of dual antiplatelet therapy has emerged as a bleeding reduction strategy.
42. Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials.
作者: Behnood Bikdeli.;David Erlinge.;Marco Valgimigli.;Adnan Kastrati.;Yaling Han.;Philippe Gabriel Steg.;Rod H Stables.;Roxana Mehran.;Stefan K James.;Enrico Frigoli.;Patrick Goldstein.;Yi Li.;Adeel Shahzad.;Stefanie Schüpke.;Ghazaleh Mehdipoor.;Shmuel Chen.;Björn Redfors.;Aaron Crowley.;Zhipeng Zhou.;Gregg W Stone.
来源: Circulation. 2023年148卷16期1207-1219页
The benefit:risk profile of bivalirudin versus heparin anticoagulation in patients with non-ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) is uncertain. Study-level meta-analyses lack granularity to provide conclusive answers. We sought to compare the outcomes of bivalirudin and heparin in patients with non-ST-segment-elevation myocardial infarction undergoing PCI.
43. Common Variants on FGD5 Increase Hazard of Mortality or Rehospitalization in Patients With Heart Failure From the ASCEND-HF Trial.
作者: Hongsheng Gui.;W H Wilson Tang.;Stephan Francke.;Jia Li.;Ruicong She.;Peter Bazeley.;Naveen L Pereira.;Kirkwood Adams.;Jasmine A Luzum.;Thomas M Connolly.;Adrian F Hernandez.;Candace D McNaughton.;L Keoki Williams.;David E Lanfear.
来源: Circ Heart Fail. 2023年16卷9期e010438页
Heart failure remains a global health burden, and patients hospitalized are particularly at risk, but genetic associates for subsequent death or rehospitalization are still lacking.
44. Short-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.
作者: Toshiki Kuno.;Atsuyuki Watanabe.;Satoshi Shoji.;Tomohiro Fujisaki.;Hiroki Ueyama.;Hisato Takagi.;Pierre Deharo.;Thomas Cuisset.;Sripal Bangalore.;Roxana Mehran.;Gregg W Stone.;Shun Kohsaka.;Deepak L Bhatt.
来源: Circ Cardiovasc Interv. 2023年16卷9期e013242页
Short-term (≤6 months) dual antiplatelet therapy (DAPT) and DAPT de-escalation become attractive for patients with acute coronary syndrome.
45. Temporal Trends and Lesion Sets for Persistent Atrial Fibrillation Ablation: A Meta-Analysis With Trial Sequential Analysis and Meta-Regression.
作者: Arunashis Sau.;Sharan Kapadia.;Sayed Al-Aidarous.;James Howard.;Afzal Sohaib.;Markus B Sikkel.;Ahran Arnold.;Jonathan W Waks.;Daniel B Kramer.;Nicholas S Peters.;Fu Siong Ng.
来源: Circ Arrhythm Electrophysiol. 2023年16卷9期e011861页
Ablation for persistent atrial fibrillation (PsAF) has been performed for over 20 years, although success rates have remained modest. Several adjunctive lesion sets have been studied but none have become standard of practice. We sought to describe how the efficacy of ablation for PsAF has evolved in this time period with a focus on the effect of adjunctive ablation strategies.
46. Graft Failure After Coronary Artery Bypass Grafting and Its Association With Patient Characteristics and Clinical Events: A Pooled Individual Patient Data Analysis of Clinical Trials With Imaging Follow-Up.
作者: Mario Gaudino.;Sigrid Sandner.;Kevin R An.;Arnaldo Dimagli.;Antonino Di Franco.;Katia Audisio.;Lamia Harik.;Roberto Perezgrovas-Olaria.;Giovanni Soletti.;Stephen E Fremes.;David L Hare.;Alexander Kulik.;Andre Lamy.;Joyce Peper.;Marc Ruel.;Jurrien M Ten Berg.;Laura M Willemsen.;Qiang Zhao.;Daniel M Wojdyla.;Deepak L Bhatt.;John H Alexander.;Bjorn Redfors.
来源: Circulation. 2023年148卷17期1305-1315页
Graft patency is the postulated mechanism for the benefits of coronary artery bypass grafting (CABG). However, systematic graft imaging assessment after CABG is rare, and there is a lack of contemporary data on the factors associated with graft failure and on the association between graft failure and clinical events after CABG.
47. Epicardial Adipose Tissue Assessed by Computed Tomography and Echocardiography Are Associated With Adverse Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.
作者: Bryan Chong.;Jayanth Jayabaskaran.;Jitesh Ruban.;Rachel Goh.;Yip Han Chin.;Gwyneth Kong.;Cheng Han Ng.;Chaoxing Lin.;Shaun Loong.;Mark D Muthiah.;Chin Meng Khoo.;Ezman Shariff.;Mark Y Chan.;Fannie Lajeunesse-Trempe.;Andre Tchernof.;Parag Chevli.;Anurag Mehta.;Mamas A Mamas.;Georgios K Dimitriadis.;Nicholas W S Chew.
来源: Circ Cardiovasc Imaging. 2023年16卷5期e015159页
Epicardial adipose tissue (EAT) has garnered attention as a prognostic and risk stratification factor for cardiovascular disease. This study, via meta-analyses, evaluates the associations between EAT and cardiovascular outcomes stratified across imaging modalities, ethnic groups, and study protocols.
48. Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials.
作者: Kashvi Gupta.;John A Spertus.;Mary Birmingham.;Kensey L Gosch.;Mansoor Husain.;Dalane W Kitzman.;Bertram Pitt.;Sanjiv J Shah.;James L Januzzi.;Ildiko Lingvay.;Javed Butler.;Mikhail Kosiborod.;David E Lanfear.
来源: Circulation. 2023年148卷3期220-228页
Health status outcomes, including symptoms, function, and quality of life, are worse for Black compared with White patients with heart failure. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce cardiovascular mortality and improve health status in patients with heart failure, but whether the health status benefit of SGLT2is is similar across races is not established. The objective of this study was to compare the treatment effect of SGLT2is (versus placebo) on health status for Black compared with White patients with heart failure.
49. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF.
作者: Josephine Harrington.;Anthony P Carnicelli.;Kaiyuan Hua.;Lars Wallentin.;Manesh R Patel.;Stefan H Hohnloser.;Robert P Giugliano.;Keith A A Fox.;Ziad Hijazi.;Renato D Lopes.;Sean D Pokorney.;Hwanhee Hong.;Christopher B Granger.
来源: Circulation. 2023年147卷23期1748-1757页
There is uncertainty surrounding the use of direct oral anticoagulants (DOACs) in patients with kidney dysfunction.
50. Oligogenic Architecture of Rare Noncoding Variants Distinguishes 4 Congenital Heart Disease Phenotypes.
作者: Mengyao Yu.;Matthew Aguirre.;Meiwen Jia.;Ketrin Gjoni.;Aldo Cordova-Palomera.;Chad Munger.;Dulguun Amgalan.;X Rosa Ma.;Alexandre Pereira.;Catherine Tcheandjieu.;Christine Seidman.;Jonathan Seidman.;Martin Tristani-Firouzi.;Wendy Chung.;Elizabeth Goldmuntz.;Deepak Srivastava.;Ruth J F Loos.;Nathalie Chami.;Heather Cordell.;Martina Dreßen.;Bertram Mueller-Myhsok.;Harald Lahm.;Markus Krane.;Katherine S Pollard.;Jesse M Engreitz.;Sarah A Gagliano Taliun.;Bruce D Gelb.;James R Priest.
来源: Circ Genom Precis Med. 2023年16卷3期258-266页
Congenital heart disease (CHD) is highly heritable, but the power to identify inherited risk has been limited to analyses of common variants in small cohorts.
51. Long-Term Effect of Weight Regain Following Behavioral Weight Management Programs on Cardiometabolic Disease Incidence and Risk: Systematic Review and Meta-Analysis.
作者: Jamie Hartmann-Boyce.;Annika Theodoulou.;Jason L Oke.;Ailsa R Butler.;Anastasios Bastounis.;Anna Dunnigan.;Rimu Byadya.;Linda J Cobiac.;Peter Scarborough.;F D Richard Hobbs.;Falko F Sniehotta.;Susan A Jebb.;Paul Aveyard.
来源: Circ Cardiovasc Qual Outcomes. 2023年16卷4期e009348页
Behavioral weight management programs (BWMPs) enhance weight loss in the short term, but longer term cardiometabolic effects are uncertain as weight is commonly regained. We assessed the impact of weight regain after BWMPs on cardiovascular risk factors, diabetes, and cardiovascular disease.
52. Genetic Risk of Primary Aldosteronism and Its Contribution to Hypertension: A Cross-Ancestry Meta-Analysis of Genome-Wide Association Studies.
作者: Tatsuhiko Naito.;Kosuke Inoue.;Kyuto Sonehara.;Ryuta Baba.;Takaya Kodama.;Yu Otagaki.;Akira Okada.;Kiyotaka Itcho.;Kazuhiro Kobuke.;Shinji Kishimoto.;Kenichi Yamamoto.; .;Takayuki Morisaki.;Yukihito Higashi.;Nobuyuki Hinata.;Koji Arihiro.;Noboru Hattori.;Yukinori Okada.;Kenji Oki.
来源: Circulation. 2023年147卷14期1097-1109页
Hypertension imposes substantial health and economic burden worldwide. Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, causing cardiovascular events at higher risk compared with essential hypertension. However, the germline genetic contribution to the susceptibility of PA has not been well elucidated.
53. Optimal Hemostatic Band Duration After Transradial Angiography or Intervention: Insights From a Mixed Treatment Comparison Meta-Analysis of Randomized Trials.
作者: Muhammad Haisum Maqsood.;Samir Pancholy.;Kristin A Tuozzo.;Nicole Moskowitz.;Sunil V Rao.;Sripal Bangalore.
来源: Circ Cardiovasc Interv. 2023年16卷2期e012781页
The optimal duration of hemostatic compression post transradial access is controversial. Longer duration increases the risk of radial artery occlusion (RAO) while shorter duration increases the risk of access site bleeding or hematoma. As such, a target of 2 hours is typically used. Whether a shorter or longer duration is better is not known.
54. Sex Differences in 10-Year Outcomes After Percutaneous Coronary Intervention With Drug-Eluting Stents: Insights From the DECADE Cooperation.
作者: J J Coughlan.;Lorenz Räber.;Salvatore Brugaletta.;Sebastian Kufner.;Michael Maeng.;Lisette Okkels Jensen.;Luis Ortega-Paz.;Sarah Bär.;Karl-Ludwig Laugwitz.;Morten Madsen.;Dik Heg.;Alp Aytekin.;Stephan Windecker.;Kevin Kris Warnakula Olesen.;Manel Sabaté.;Adnan Kastrati.;Salvatore Cassese.
来源: Circulation. 2023年147卷7期575-585页
Although some studies have investigated sex-related outcomes up to 5 years after percutaneous coronary intervention (PCI), analyses at longer follow-up (ie, to 10 years) in large cohorts treated exclusively with drug-eluting stent (DES) platforms are lacking. Therefore, this study aimed to define whether sex-related differences in long-term outcomes after PCI persist both in the DES era and at longer-term follow-up.
55. Prospective Association of Daily Steps With Cardiovascular Disease: A Harmonized Meta-Analysis.
作者: Amanda E Paluch.;Shivangi Bajpai.;Marcel Ballin.;David R Bassett.;Thomas W Buford.;Mercedes R Carnethon.;Ariel Chernofsky.;Erin E Dooley.;Ulf Ekelund.;Kelly R Evenson.;Deborah A Galuska.;Barbara J Jefferis.;Lingsong Kong.;William E Kraus.;Martin G Larson.;I-Min Lee.;Charles E Matthews.;Robert L Newton.;Anna Nordström.;Peter Nordström.;Priya Palta.;Alpa V Patel.;Kelley Pettee Gabriel.;Carl F Pieper.;Lisa Pompeii.;Erika Rees-Punia.;Nicole L Spartano.;Ramachandran S Vasan.;Peter H Whincup.;Shengping Yang.;Janet E Fulton.; .
来源: Circulation. 2023年147卷2期122-131页
Taking fewer than the widely promoted "10 000 steps per day" has recently been associated with lower risk of all-cause mortality. The relationship of steps and cardiovascular disease (CVD) risk remains poorly described. A meta-analysis examining the dose-response relationship between steps per day and CVD can help inform clinical and public health guidelines.
56. Response by Zhao et al to Letter Regarding Article, "Associations of Dietary Cholesterol, Serum Cholesterol, and Egg Consumption With Overall and Cause-Specific Mortality: Systematic Review and Updated Meta-Analysis".57. Reduced Mortality With Antiplatelet Therapy Deescalation After Percutaneous Coronary Intervention in Acute Coronary Syndromes: A Meta-Analysis.
作者: Tullio Palmerini.;Antonio Giulio Bruno.;Mauro Gasparini.;Giulia Rizzello.;Hyo-Soo Kim.;Jeehoon Kang.;Kyung-Woo Park.;Joo-Yong Hahn.;Young Bin Song.;Hyeon-Cheol Gwon.;Eun Ho Choo.;Mahn-Won Park.;Chan Joon Kim.;Kiyuk Chang.;Thomas Cuisset.;Nevio Taglieri.;Byeong-Keuk Kim.;Yangsoo Jang.;Elena Nardi.;Francesco Saia.;Matheusz Orzalkiewicz.;Francesco Chietera.;Gabriele Ghetti.;Nazzareno Galiè.;Gregg W Stone.
来源: Circ Cardiovasc Interv. 2022年15卷11期906-914页
Antiplatelet therapy deescalation has been suggested as an alternative to standard treatment with potent dual antiplatelet therapy (DAPT) for 1 year in low bleeding risk patients with acute coronary syndromes undergoing percutaneous coronary intervention to mitigate the increased risk of bleeding. Whether this strategy preserves the ischemic and survival benefits of potent DAPT is uncertain.
58. Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
作者: Eloisa Colin-Ramirez.;Nariman Sepehrvand.;Sarah Rathwell.;Heather Ross.;Jorge Escobedo.;Peter Macdonald.;Richard Troughton.;Clara Saldarriaga.;Fernando Lanas.;Robert Doughty.;Finlay A McAlister.;Justin A Ezekowitz.
来源: Circ Heart Fail. 2023年16卷1期e009879页
Sodium restriction is a nonpharmacologic treatment suggested by practice guidelines for the management of patients with heart failure (HF). In this study, we synthesized the data from randomized controlled trials (RCTs) evaluating the effects of sodium restriction on clinical outcomes in patients with HF.
59. Pathway-Specific Polygenic Risk Scores Identify Obstructive Sleep Apnea-Related Pathways Differentially Moderating Genetic Susceptibility to Coronary Artery Disease.
作者: Matthew O Goodman.;Brian E Cade.;Neomi A Shah.;Tianyi Huang.;Hassan S Dashti.;Richa Saxena.;Martin K Rutter.;Peter Libby.;Tamar Sofer.;Susan Redline.
来源: Circ Genom Precis Med. 2022年15卷5期e003535页
Obstructive sleep apnea (OSA) and its features, such as chronic intermittent hypoxia, may differentially affect specific molecular pathways and processes in the pathogenesis of coronary artery disease (CAD) and influence the subsequent risk and severity of CAD events. In particular, competing adverse (eg, inflammatory) and protective (eg, increased coronary collateral blood flow) mechanisms may operate, but remain poorly understood. We hypothesize that common genetic variation in selected molecular pathways influences the likelihood of CAD events differently in individuals with and without OSA, in a pathway-dependent manner.
60. Direct Oral Anticoagulants Versus Antiplatelet Therapy After Transcatheter Aortic Valve Replacement: A Meta-Analysis of Randomized Trials.
作者: Ayman Elbadawi.;Alexander T Dang.;Ramy Sedhom.;Mohamed Hamed.;Mennaallah Eid.;Harsh Golwala.;Sachin S Goel.;Mamas A Mamas.;Islam Y Elgendy.
来源: Circ Cardiovasc Interv. 2022年15卷9期e012194页 |